Followers | 4054 |
Posts | 152164 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Monday, December 30, 2013 4:14:46 PM
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
Alert
Quidel (NASDAQ:QDEL)
Intraday Stock Chart
Today : Monday 30 December 2013
Click Here for more Quidel Charts. Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
SAN DIEGO, CA--(Marketwired - Dec 30, 2013) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue Group B Strep Assay. AmpliVue is Quidel's non-instrumented molecular diagnostic test that employs a novel amplification technology with an easy-to-use, hand-held device. The AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification (HDA) with Quidel's well-established expertise in lateral flow technology to detect Group B Streptococcus (GBS) from enriched broth cultures of specimens from antepartum women.
GBS is responsible for illness in people of all ages, but it is a particularly serious pathogen for newborns in whom it can cause life-threatening sepsis, pneumonia and sometimes meningitis with a risk for long lasting effects, including deafness and developmental disabilities.1 According to the Centers for Disease Control and Prevention (CDC), roughly 10% to 30% of pregnant women carry GBS that can be transmitted to the newborn at delivery. CDC guidelines recommend that all pregnant women should be tested for GBS infection between 35 and 37 weeks of pregnancy.2
Although more rare, serious GBS infections can also occur in adults, leading to bloodstream infections, pneumonia, and other infections that can be fatal.3
"We are pleased to receive 510(k) clearance for our AmpliVue Group B Strep assay," said Douglas Bryant, president and chief executive officer of Quidel Corporation. "We can now provide the hospital laboratories with another AmpliVue assay for fast, accurate infectious disease testing without the need for additional investments in expensive equipment."
The AmpliVue Group B Strep assay now enables laboratories of all sizes to perform highly sensitive and specific molecular tests and is Quidel's second assay to launch in the hand-held, disposable AmpliVue format. The AmpliVue C. difficile assay was launched earlier this year for the detection of toxigenic Clostridium difficile bacterial DNA. Both assays are now available for sale throughout the U.S. and Europe. Diagnostic tests for other analytes of interest that will use the novel AmpliVue platform are in development.
1 http://www.cdc.gov/groupbstrep/about/index.html
2 http://www.cdc.gov/groupbstrep/about/fast-facts.html
3 http://www.cdc.gov/groupbstrep/about/adults.html
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia® and AmpliVue® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Recent QDEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:45:59 PM
- QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer • Business Wire • 09/10/2024 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:18:19 PM
- VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S. • Business Wire • 08/29/2024 11:00:00 AM
- QuidelOrtho to Participate in Upcoming Investor Conferences • Business Wire • 08/19/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 07:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:08:04 PM
- QuidelOrtho Reports Second Quarter 2024 Financial Results • Business Wire • 07/31/2024 08:05:00 PM
- Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 • PR Newswire (US) • 07/23/2024 11:17:00 PM
- QuidelOrtho to Report Second Quarter 2024 Financial Results • Business Wire • 07/17/2024 11:00:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Shareholders • PR Newswire (US) • 06/10/2024 09:45:00 AM
- Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:14:53 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2024 08:14:29 PM
- QuidelOrtho Corporation f/k/a Quidel Corporation Class Action: The Gross Law Firm Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDEL • PR Newswire (US) • 05/29/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 10:26:50 PM
- QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference • Business Wire • 05/23/2024 11:00:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 11, 2024 in QuidelOrtho Corporation f/k/a Quidel Corporation Lawsuit - QDEL • PR Newswire (US) • 05/21/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:21:05 PM
- QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL • PR Newswire (US) • 05/17/2024 09:45:00 AM
- QuidelOrtho Opens New Distribution Center in Pedricktown, NJ • Business Wire • 05/15/2024 08:05:00 PM
- The Gross Law Firm Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 05/14/2024 09:45:00 AM
- Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:07:08 PM
- QuidelOrtho Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM